Selected immatics press releases for your convenient download
- -- 02 June 2010
- immatics enters Collaboration with the National Cancer Institute (NCI) to Advance the Development of IMA950 for Glioblastoma
- -- 16 February 2010
- immatics Enters Collaboration with Cancer Research UK to Develop Multi-target Rationally Designed Therapeutic Cancer Vaccine
- -- 29 September 2009
- immatics appoints Carsten Reinhardt as Chief Medical Officer
- -- 17 June 2009
- immatics biotechnologies significantly improves XPRESIDENTâ„¢ technology platform
- -- 02 March 2009
- immatics completes patient recruitment in phase II study with cancer vaccine IMA901 for renal cell cancer
- -- 26 January 2009
- immatics wins 29th German Industry's Innovation Award (Innovationspreis der deutschen Wirtschaft)
- -- 14 July 2008
- immatics obtains important U.S. and European patents
- -- 09 July 2008
- immatics appoints Paul G. Higham as Chief Executive Officer
- -- 08 July 2008
- immatics receives 3 research grants totaling 1.4 mn € to advance its early-stage cancer immunotherapy programs
- -- 22 April 2008
- immatics launches Phase I/II study of IMA910 cancer vaccine in colorectal cancer
- -- 11 January 2008
- immatics opens office in Munich
- -- 30 November 2007
- immatics is laureate in the "2007 STEP Award"
- -- 24 September 2007
- immatics launches Phase 2 study on cancer vaccine IMA901
- -- 06 June 2007
- FierceBiotech names immatics biotechnologies one of the “Fierce 15” biotech companies of 2007
- -- 14 March 2007
- immatics granted orphan drug status for therapeutic cancer vaccine IMA901
- -- 08 February 2007
- immatics receives €40 million in second round of funding / Largest private biotech financing round in Germany since 2001
- -- 10 October 2006
- immatics successfully concludes Phase 1 clinical study on potential renal cell cancer vaccine
- -- 06 September 2006
- immatics receives BMBF grant for new cancer projects
- -- 07 March 2006
- Recruitment goal for Phase 1 study reached sooner than planned
- -- 29 November 2005
- immatics launches Phase 1 clinical study on cancer vaccine IMA901
- -- 22 November 2005
- immatics strengthens Supervisory Board with Dr. Klaus Stöckemann
- -- 01 August 2005
- immatics receives BMBF grant for development of product candidates for cancer immunotherapy of gastric carcinoma
- -- 15 April 2005
- immatics receives recognition for progress in cancer immunotherapy
- -- 26 January 2005
- immatics adds to management team
- -- 28 April 2004
- immatics increases first round of financing to EUR 8.25 million
- -- 11 February 2004
- immatics receives EUR 7.75 million in initial round of funding
immatics enters Collaboration with the National Cancer Institute (NCI) to Advance the Development of IMA950 for Glioblastoma
Multi-target therapeutic cancer vaccine IMA950 to enter second clinical phase I study for glioblastoma, the most aggressive form of brain cancer
Tuebingen, 2 June, 2010 - immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced that it has signed a Clinical Trial Agreement with the Center for Cancer Research (CCR), National Cancer Institute (NCI), USA. The Agreement covers the clinical development of immatics’ therapeutic cancer vaccine IMA950 which is to be evaluated in the field of brain cancer, specifically glioblastoma, the most aggressive form of brain cancer.
Under the terms of the agreement, CCR will sponsor and conduct a phase I trial of IMA950 which will be carried out at the National Institute of Health’s (NIH’s) Facility in Bethesda, Maryland, U.S. The phase I trial will evaluate IMA950 in stable or recurrence-free glioblastoma patients following standard radiochemotherapy with temozolomide.
The principal investigator of the study is Dr. Howard Fine, Chief of the Neuro-Oncology Branch at the National Cancer Institute. immatics will collaborate with CCR and will also be responsible for drug supply for the study as well as undertaking immunomonitoring of the treated patients.
This collaboration follows an agreement immatics signed with Cancer Research UK in February for the clinical development of IMA950 in glioblastoma. The Cancer Research UK sponsored study will treat newly diagnosed patients with IMA950 in combination with radio-chemotherapy while this study at the NCI will treat patients after successful radio-chemotherapy with standalone IMA950. The different protocols for these two studies should mean that they provide complementary data reflecting the different clinical situations experienced by glioblastoma patients.
Paul Higham, CEO of immatics said: “We are delighted to be collaborating with such a prestigious organization as the National Cancer Institute to help us to develop our third therapeutic vaccine, IMA950. Our ability to secure two such highly regarded collaborators to advance IMA950 into the clinic demonstrates the significant interest in immatics’ novel therapeutic vaccines and the need for a much improved treatment option for glioblastoma. We very much look forward to working with the NCI to further develop IMA950 and to evaluate how it may be of benefit in this devastating disease.”
About IMA950
IMA950 is a therapeutic cancer vaccine generated through immatics’ proprietary XPRESIDENT™ technology. It consists of 11 tumor-associated peptides (TUMAPs) which the immatics platform selected on the basis of their natural presentation by tumor tissue, overexpression in tumor vs. healthy tissue, immunogenicity and their relevance to tumor function. This unique approach to rationally designed therapeutic vaccines which are a combination of multiple, highly relevant tumor peptides is at the core of all immatics’ clinical programs.